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Abstract
Background: Dengue infection ranks as one of the most significant viral diseases of the globe. Currently, there is no specific
vaccine or antiviral therapy for prevention or treatment. Monocytes/macrophages are the principal target cells for dengue
virus and are responsible for disseminating the virus after its transmission. Dengue virus enters target cells via receptor-
mediated endocytosis after the viral envelope protein E attaches to the cell surface receptor. This study aimed to investigate
the effect of silencing the CD-14 associated molecule and clathrin-mediated endocytosis using siRNA on dengue virus entry
into monocytes.
Methodology/Principal Findings: Gene expression analysis showed a significant down-regulation of the target genes
(82.7%, 84.9 and 76.3% for CD-14 associated molecule, CLTC and DNM2 respectively) in transfected monocytes. The effect of
silencing of target genes on dengue virus entry into monocytes was investigated by infecting silenced and non-silenced
monocytes with DENV-2. Results showed a significant reduction of infected cells (85.2%), intracellular viral RNA load (73.0%),
and extracellular viral RNA load (63.0%) in silenced monocytes as compared to non-silenced monocytes.
Conclusions/Significance: Silencing the cell surface receptor and clathrin mediated endocytosis using RNA interference
resulted in inhibition of the dengue virus entry and subsequently multiplication of the virus in the monocytes. This might
serve as a novel promising therapeutic target to attenuate dengue infection and thus reduce transmission as well as
progression to severe dengue hemorrhagic fever.
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Introduction
Dengue infection ranks as one of the most clinically significant
and prevalent mosquito-borne viral diseases of the globe. It is an
expanding public health problem particularly in the tropical and
subtropical areas [1]. Following an incubation period of 3 to 14
days, fever and a variety of symptoms occur, coinciding with the
appearance of dengue virus (DENV) in blood [2]. Immunopath-
ological studies suggest that many tissues may be involved during
dengue infection, as viral antigens are expressed in liver, lymph
node, spleen and bone marrow [3,4,5]. DENV can infect and
replicate in different mammalian cells, including monocytes,
macrophages, dendritic cells, B and T leukocytes, endothelial cells,
and bone marrow-, hepatoma-, neuroblastoma- and kidney-derived
cells. Based on several observations and antibody dependent
enhancement hypothesis, monocyte lineage cells are the major
target for DENV [6,7,8,9]. These cells are responsible for
replication and dissemination of the virus after the infection from
mosquito bites. Since monocytes/macrophages are active phago-
cytic cells with cytoplasmic lysosomal components that can
eliminate microorganisms [10], the interaction of DENV with
monocytes/macrophages may have detrimental effects on both
virus and cells. DENV infected monocytes/macrophages release
soluble mediators that strongly influence the biological character-
istics of endothelial cells and the hematopoietic cell population. This
indicates that the interactions between DENV and monocytes/
macrophages are important in the pathogenesis of dengue
hemorrhagic fever (DHF) and dengue shock syndrome (DSS).
Previous studies suggest that DENV enters target cells after the
viral envelope protein E attaches to an uncharacterized cell
receptor [11]. Current studies indicate that multiple cell surface
molecules, including GRP78 [12], heat shock proteins (Hsp) 70
and 90 [13,14], lipopolysaccharide-binding CD 14-associated
molecule [8,15,16], laminin receptor [17], mannose receptor [18],
and DC-SIGN [19], were involved in DENV binding and
subsequent virus infection in different target cells. CD-14
associated molecule has implicated as a surface receptors on
monocytes for DENV-2 entry [8,15,16]. CD-14 associated
molecule is a membrane protein expressed by monocytes, antigen
presenting cells and neutrophils and plays a role in the innate
immune system. CD-14 associated molecule is necessary for the
cellular response in infections mediated by bacterial lipopolysac-
charide, which activates monocytes for the expression of cytokines,
growth factors, and procoagulatory factors [20]. Failure of
interaction of lipopolysaccharide with CD-14 has been implicated
in susceptibility to infectious diseases [21].
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the cell cytoplasm by membrane fusion and this process may take
place within intracellular vesicles (pH-dependent). This endocytic
internalization offers the advantage of guiding the virion to an
adequate site for replication and bypassing many cytoplasmatic
barriers. Several endocytic pathways have recently been identified
[22], but the clathrin-mediated endocytosis has been demonstrated
as the main entry pathway for DENV-2 [23,24,25]. Clathrin-
mediated endocytosis plays a crucial role in the formation of
coated vesicles, antigen presentation, nutrient acquisition, clear-
ance of apoptotic cells, pathogen entry, receptor regulation,
hypertension, and synaptic transmission.
Despite the importance and increasing incidence of DENV as a
human pathogen, there are no antiviral agents or vaccines
available for treatment or prevention. It is necessary to develop
new therapeutic strategies by targeting the DENV binding
molecules on susceptible host cells. The blockade of DENV entry
into the host cell is an interesting antiviral strategy because it
represents a barrier to suppress the onset of infection [26].
RNA interference (RNAi) is a potent and specific post-
transcriptional gene silencing event induced by double stranded
RNAs, which degrade the target mRNA that has the homologous
sequence [27,28]. RNAi has become the most useful and powerful
research tool for studies of gene functions, regulation of gene
transcriptions and gene therapies over the last few years [29].
Compared to other traditional gene silencing methods, it has the
advantage of significantly enhanced potency, specificity and
versatility [30,31]. The mediators of sequence specific mRNA
degradation are small interfering RNAs (siRNA). siRNAs are 21 to
29 nucleotide in length and carry 59 phosphate and 39 hydroxyl
termini and 2-nt 39 overhangs [32,33]. siRNAs can effectively
suppress target genes in mammalian cells without triggering
interferon production [30,34]. The transfection of siRNAs into
mammalian cells resulted in a potent, long-lasting reaction
typically several days and extraordinarily specific post-transcrip-
tional silencing of target genes [33,35]. The use of siRNA is
suitable for the design of novel gene-specific therapeutics by
directly targeting the mRNAs of the related genes and holds great
promise for the application of gene-specific therapies in treating
acute diseases such as viral infection, cancer, and, perhaps, acute
inflammation. Several preliminary studies show that, RNAi has
been used effectively to inhibit the replication of different
pathogenic viruses in culture, including respiratory syncytial virus,
hepatitis viruses, influenza virus, poliovirus, rhinovirus and human
immunodeficiency virus [30,35].
This study aimed to investigate the possible usage of siRNA in
the reduction of DENV entry and replication in human
monocytes by targeting the monocytes attachment receptor and
clathrin-mediated endocytosis. CD-14 associated molecule has
been targeted as an attachment receptor on the surface of
monocytes. Besides that, two main components of the clathrin-
mediated endocytosis pathway has also been selected; Clathrin
heavy polypeptide (CLTC) which is required for clathrin-coated
pits formation, and Dynamin 2 (Human-DNM2) which is
important for pinching off of endocytic vesicles from the plasma
membrane. Three siRNAs were designed for each target gene
(CD-14 associated molecule, CLTC, and DNM2) to guarantee a
greater potency than a single siRNA and eliminate off-targets
effect.
Methods
Isolation and purification of monocytes
Peripheral blood samples from different healthy donors who
were not associated with prior dengue infection were collected in
EDTA tubes. Peripheral blood mononuclear cells (PBMC) were
isolated by density centrifugation with Ficoll-paque as described
previously [36]. Human monocytes were purified by depletion of
non-monocytes followed by negative selection using a MACS
human monocytes isolation kit II (cat #: 130-091-153, Miltenyi
Biotec GmbH, Gladbach, Germany) in accordance to manufac-
turer’s protocol. Briefly, non-monocytes were indirectly magnet-
ically labeled with a cocktail of biotin-conjugated mouse
monoclonal antibodies against CD3, CD7, CD16, CD19, CD56,
CD123 and Glycohorin A, as primary labeling reagents, and anti-
biotin monoclonal antibodies that were conjugated to MicroBeads,
as secondary labeling reagents. The magnetically labeled non-
monocytes were depleted by retaining them on a MACSH column
in the magnetic field of a MACS separator, while the unlabeled
monocytes passed through the column. Written informed consent
was obtained from blood donors. Ethical clearance (REF No.:
794.5) was obtained for the main project from the Scientific and
Ethical Committee at the University Malaya Medical Center prior
to commencement of study.
siRNA sequences
The nucleotide sequences for the CD-14 associated molecule
(NM_000591), CLTC (NM_004859), and DNM2 (NM_001005360)
transcripts were obtained from GenBank. siRNA sequences were
designed by using the web-based tool IDT SciTools RNAi Design
available from Integrated DNA Technologies (IDT), Inc. at www.
idtdna.com. Three siRNAs were designed for each gene (Table 1). A
pool consists of the three siRNAs for each gene was custom chemically
synthesized by 1
st BASE Pte Ltd, Singapore. The synthesized siRNAs
were purified by HPLC, and a 29-O-methyl modification at position 2
was introduced to deactivate the off-target activity of the siRNA
without compromising the silencing effectiveness [37].
Transfection of monocytes with siRNA
The siRNAs were transfected using siLentFect
TM Lipid Reagent
(cat #: 170-3361, Bio-Rad Laboratories, Hercules, CA, USA).
Transfection was achieved at a cell density of 1.5610
5 cells/well in
a 24 wells plate by using 1.0 ml of lipid transfection reagent and
optimized siRNA concentration (25, 50, and 50 nM for CD14
associate molecule, CLTC, and DNM2), respectively. The positive
Author Summary
Prevention and treatment of dengue infection remain a
serious global public health priority. Extensive efforts are
required toward the development of vaccines and
discovery of potential therapeutic compounds against
the dengue viruses. Dengue virus entry is a critical step for
virus reproduction and establishes the infection. Hence,
the blockade of dengue virus entry into the host cell is an
interesting antiviral strategy as it represents a barrier to
suppress the onset of infection. This study was achieved by
using RNA interference to silence the cellular receptor, and
the clathrin mediated endocytosis that enhances the entry
of dengue virus in monocytes. Results showed a marked
reduction of infected monocytes by flow cytometry. In
addition, both intracellular and extracellular viral RNA load
was shown to be reduced in treated monocytes when
compared to untreated monocytes. Based on these
findings, this study concludes that this therapeutic
strategy of blocking the virus replication at the first stage
of multiplication might serve as a hopeful drug to mitigate
the dengue symptoms, and reduction the disease severity.
siRNA Inhibition of Dengue Virus Entry
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targeting b-actin gene. The negative control received the
siLentFect
TM Lipid Reagent plus the scramble siRNA oligonucle-
otides. After 24 h, the cells were harvested for monitoring the gene
silencing effect at the mRNA expression level while the infectious
entry was evaluated after infecting the transfected monocytes with
DENV-2 after 72 h.
Cell viability and Cytotoxicity
Cytotoxicity was tested by a fluorescent assay that measure
LDH released from cells with compromised membrane using
CytoTox-ONE
TM Homogeneous Membrane Integrity Assay
(Promega, Madison, WI) in accordance to manufacturer’s
protocol. Viable monocytes also were counted by staining with
0.4% trypan blue (Invitrogen). The number of trypan blue positive
and negative cells were counted on a hemocytometer under light
microscope. Cell counts were used to verify the LDH results.
RNA extraction
Total RNA was extracted using RNeasyH Plus Micro Kit (cat #:
74034, QIAGEN, Hilden, Germany) for gene expression analysis
and intracellular DENV quantification by reverse transcription
quantitative real-time PCR (RT-qPCR). RNA extraction was
done according to the manufacturer’s instructions. Total RNA was
purified using gDNA eliminator columns and was checked by
including no-reverse transcription control in the RT-qPCR
amplification procedure. For quantification of DENV in the
cellular supernatant, viral RNA was extracted separately from
200 ml of tissue culture supernatant using the QIAmp viral RNA
mini kit (cat #: 52904, QIAGEN, Hilden, Germany) according to
the manufacturer’s specifications.
All RNA samples were examined for their purity and concentra-
tion using Implen NanoPhotometer
TM (Implen GmbH, Munich,
Germany). All extracted samples have absorbance ratios of 1.8–2.0
at 260/280 nm, indicating all the samples were free from potentially
accumulating proteins during the RNA extraction procedure. In
addition, the absence of RNA degradation was assessed by agarose
gel electrophoresis. Isolated RNA was stored at 280uC until used.
cDNA synthesis
For gene expression analysis, 500 ng of total RNA were reverse-
transcribed into cDNA using the iScript
TM cDNA synthesis kit (cat
#: 170-8891, Bio-Rad Laboratories, Hercules, CA, USA).
Optimization of qPCR
All sequences of target gene [CD-14 (CD-14 associated
molecule); CLTC (Clathrin heavy polypeptide); and DNM2
(Dynamin 2 )], experimental control gene [ACTB (b-actin)] and
reference genes [RPL22 (ribosomal protein L22); and RPS29
(ribosomal protein S29)] were retrieved from GenBank. qPCR
primer pairs for CD-14, CLTC, DNM2, and ACTB were
designed by using Primer Express software V3.0. Primers for
RPL22 and RPS29 were obtained from published sequences [38].
Various concentrations of primer sets and a range of annealing
temperatures were analyzed to achieve optimal qPCR specificity
and efficiency (data not shown). A dissociation analysis was
performed after each qPCR runs with cDNA as a template, in
order to show that each primer set amplified the expected single
product. A pair of primer was considered valid when the efficacy
of amplification is between 90–110% with a minimum r
2 of 0.980.
Table 2 shows the primers used in this study. We used the geNorm
algorithm v3.5 [39] to determine the number and the most stable
reference genes for this study (data not shown).
qPCR and gene expression
qPCR was performed on CFX96
TM Real-Time PCR Detection
System (Bio-Rad, Hercules, CA, USA). The reaction was carried
out in a final volume of 20 ml, including 10 ml2 6iQ
TM SYBRH
Green Supermix (cat #: 170-8882, Bio-Rad Laboratories,
Hercules, CA, USA), 2 ml cDNA template, 6 ml RNase/DNase-
free sterile water and 1.0 ml (250 nM final concentration) of each
primer. qPCR was carried out with an initial 5 min hot start
activation of the polymerase at 95uC then 40 cycles of 10 sec
denaturation at 95uC, 20 sec annealing at 57.7uC with a single
fluorescence emission measurement and 30 sec extension at 72uC,
followed by 5 min at 72uC for final extension. The specificity of
amplicons was verified by melting curve analysis (74 to 95uC) with
a heating rate 0.5uC per 5 sec to verify the identity and purity of
the amplified products. qPCR experiments were performed in
triplicate. Also, no template and no-reverse transcription controls
were included. Baseline and quantification cycle (Cq) values and
gene expression analysis were done using the Bio-Rad CFX
Manager Software 1.6.
Virus propagation and titration
DENV-2 New Guinea Clone (NGC) stock was propagated in
C6/36 cells and stored at 280uC until used as described
previously [40]. Virus was titrated using the plaque formation
assay on PscloneD cells as described previously [41].
Ex-vivo monocytes infection
Infection of silenced and non-silenced monocytes was per-
formed in a 24-wells tissue culture plate. 1.5610
5 cells per well
were seeded in each well. At the time of infection, medium was
removed, DENV-2 (MOI of 2) was added, and followed by
incubation at 37uC for 2 h to allow viral adsorption. The culture
plate was gently agitated every 15 min for optimal virus to cell
contact. Thereafter, the viral supernatant was removed, and the
cells were washed three times with serum free media to remove
residual virus. Fresh complete growth RPMI 1640 medium was
added and then incubated at 37uC and 5% CO2 for 72 h prior to
harvest. Cellular supernatant was collected and stored in aliquot at
Table 1. Sequences of siRNA oligonucleotide template.
siRNA Nucleotide sequence (sense strand) Position
a
CD-14 (1) 59r(CUGCAGAAUCCUUCCUGUUACGGTC)39 72–96
CD-14 (2) 59r(CCUCUGGAAGCCACAGGACUUGCAC)39 760–784
CD-14 (3) 59r(ACAGAAUAAUGAAUGGACUCAAACT)39 1491–1515
CLTC (1) 59r(AGCCAGGACCCAGAUGUFC)39 2607–2625
CLTC (2) 59r(AUGUAUGAUGCUGCUAAGU)39 4071–4089
CLTC (3) 59r(CUCCACCAAUGACCUUAGA)39 7964–7982
DNM2 (1) 59r(GAAGGACAUCCGUGCAGCACUGGCA)39 925–949
DNM2 (2) 59r(GUACCAGUAAGCUCAGUUCCUACCC)39 1515–1539
DNM2 (3) 59r(CCCUUGACACCAUCCUGAAUGAGGG)39 3075–3099
b- actin 59r(CCAGCACAAUGAAGAUCAAGAUCAT)39 1049–1073
Scramble
b 59r(ATGGACAGAATAAATGGACTT)39
aThe position refers to the siRNA oligonucleotide position on the target gene.
bScrambled siRNA is a control used to discount any changes to the gene
expression profile that may result from the siRNA delivery method.
Three siRNAs for each target gene were designed. The experiment includes also
one Positive control siRNA for human b-actin gene and one scramble siRNA
oligonucleotide.
doi:10.1371/journal.pntd.0001410.t001
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qPCR, while monocytes were harvested for monitoring intracel-
lular infectious DENV by flow cytometry and quantification of
viral RNA copies by RT-qPCR.
Dengue virus quantification by RT-qPCR
Quantification of dengue viral RNA by RT-qPCR requires a
reliable standard curve. 10-fold serial diluted of a known copies
number of DENV RNA was diluted and used to generate the
standard curve. One-step RT-qPCR was carried out in CFX96
TM
Real-Time PCR Detection System using the iScript
TM One-Step
RT-PCR Kit with SYBRH Green (cat #: 170-8893, Bio-Rad
Laboratories, Hercules, CA, USA). After optimization, the
reaction was performed in a final volume of 25 ml, including
12.5 ml2 6SYBRH Green RT-PCR reaction mix, 6.25 ml RNase/
DNase-free sterile water and 0.5 ml (200 nM final concentration)
of each primer (Table 2), 0.25 ml iScript Reverse Transcriptase for
One-Step RT-PCR and 5 ml RNA template. The thermal cycling
profile of this assay consisted of a 30 min reverse transcription step
at 50uC, 15 min of Taq polymerase activation at 95uC, followed
by 35 cycles of PCR at 95uC of denaturing for 30 sec, 40 sec
annealing at 58.0uC and 50 sec extension at 72.0uC with a step of
a single fluorescence emission data collection followed by 10 min
at 72uC for final extension. The specificity of amplicon was
verified by melting curve analysis (72 to 95uC) with a heating rate
0.5uC per 5 sec to check the identity and purity of the amplified
products. Triplicate reactions were carried out for each sample,
and no template control was included. Cq values and number of
copies for DENV-2 RNA per sample were calculated using the
Bio-Rad CFX Manager Software 1.6.
Flow cytometry analysis
Silenced and non-silenced DENV-2 infected and non-infected
monocytes (control) were harvested at 72 h after DENV-2
infection for flow cytometric determination of DENV infection.
Cells were washed twice in PBS by centrifugation, fixed and
permeabilized in 200 ml Cytofix/Cytoperm solution (BD Biosci-
ences, San Diego, CA) for 15 min at room temperature followed
by washing twice in Cytoperm/Cytowash solution (BD Bioscienc-
es, San Diego, CA). Cells were stained using indirect staining
method. First, cells were incubated in 100 ml of MAb (anti-DENV-
2 for detection of positive samples and anti-DENV-3 as a negative
control) as a primary antibody for 1 h on ice. The cells were then
washed twice with Cytoperm/Cytowash solution and incubated
with a FITC-labeled goat anti-mouse IgG (50 ml) as a secondary
antibody at a final concentration of 3.5 mg/mL for 30 min on ice
in the dark. Cells were subsequently washed twice with an excess
amount of Cytoperm/Cytowash solution and resuspended in
0.5 ml of stain buffer (BD Biosciences, San Diego, CA). As a final
point, 50,000 events were acquired on a FACScaliber using Cell
Quest software (Becton Dickinson Immunocytometry System, San
Diego, CA). The percentage of dengue positive cells was
determined from FITC fluorescence histogram using a region
that was defined based on analysis of the infected control
monocytes.
Statistical analysis
All assays (Cytotoxicity assay, gene expression analysis,
monocytes infection experiment, flow cytometry detection of
infected cells, and intracellular and extracellular quantification of
viral RAN by RT-qPCR) were done in triplicate. All statistical
analyses were performed using GraphPad Prism version 5.01
(GraphPad Software, San Diego, CA). P values,0.05 were
considered significant. Error bars are expressed as 6 SD.
Results
siRNA delivery
Our aim was to perform an efficient siRNA transfection to
achieve a maximum silencing effect of the target mRNAs. We
have optimized the transfection experiment to produce a
maximum silencing with minimal or no toxicity to the host cells.
We observed that the highest efficiency of siRNA transfection
could be achieved at a cell density of 1.5610
5 cells/well in a 24
wells plate by using 1.0 ml of siLentFect Lipid transfection reagent.
The optimal siRNA concentration was 25, 50, and 50 nM for
CD14 associate molecule, CLTC and DNM2 respectively (data
not shown).
Efficiency of silencing target gene
RT-qPCR was performed with mRNA extracted from the
transfected monocytes to examine the knockdown level of the
target mRNAs induced by siRNA transfection. Gene expression
Table 2. Primer sequences.
Accession Number Gene symbol Sequence (59R39) (bp)
( NM_000591) CD-14 F: GACAGGGCGTTCTTGGCTCG
R: ACAGAGAGCCGCCATCAGTCC
187
(NM_004859) CLTC F: CCACAATACTCCACCAATGACCTTA
R: CCCATTTTAAGTGGCTCCACCTCTC
97
(NM_001005360) DNM2 F: GGCATTCGAGGCCATTGT
R: CATTTCAGACAGGGCTCTTTCA
60
(NM_001101) ACTB F: CCTTCTACAATGAGCTGCGTGTG
R: AGGTAGTCAGTCAGGTCCCG
301
(NM_000983) RPL22 F: TCGCTCACCTCCCTTTCTAA
R: TCACGGTGATCTTGCTCTTG
250
(NM_001030001) RPS29 F: GCACTGCTGAGAGCAAGATG
R: ATAGGCAGTGCCAAGGAAGA
213
(NC001477) DENV_NS5 F: GGAAGGAGAAGGACTGCACA
R: ATTCTTGTGTCCCATCCTGCT
104
Primer sequences of the target genes, positive control gene, optimal reference genes and DENV NS5.
doi:10.1371/journal.pntd.0001410.t002
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Manager Software 1.6, which is based on the algorithm outlined
previously [39]. Results were expressed as normalized fold
expression as compared to the non-transfected control and
normalized to reference genes. First, we screened the silencing
efficiency of pooled siRNAs, which comprised of three different
siRNAs targeting the same gene as shown in Figure 1. The
knockdown levels were 82.4%61.9, 86.0%60.6 and 78.5%63.0
for pooled CD-14 associated molecule siRNA, pooled CLTC
siRNA and pooled DNM2 siRNA respectively (One-way ANOVA
with Dunnett’s post-test, P,0.0001). The monocytes were then
transfected with a combination of the three different siRNA pools
to target on all the three genes simultaneously. We found that
there are no significant differences in the knockdown level for all
the genes (82.7%62.4, 84.9%61.2 and 76.3%61.7 for CD-14
associated molecule, CLTC and DNM2 respectively) when
compared to separate transfection (Two-way ANOVA with
Bonferroni post-test, P.0.05). Furthermore, scramble siRNA
had no inhibitory effect on any gene expression and observation
was similar to the non-transfected control (Figure 1).
Cytotoxicity testing
Cytotoxicity from the siRNA delivery was monitored by
comparing viable cell numbers in cultures that were transfected
with siRNA to that of non-transfected control. In this study,
cytotoxicity was determined by measuring LDH released from
cells with compromised membrane. Transfection experiment was
optimized by treating the monocytes with increasing concentration
of siRNA and transfection reagent. Results showed no evidence of
toxicity regardless of the concentration of siRNA used and a mild
toxicity with the increase of transfection reagent (data not shown).
Furthermore, no cytotoxicity effect was observed at 72 h post-
transfection of combined siRNAs in monocytes (.90% viable
cells) (One-way ANOVA with Dunnett’s post-test, P.0.05). This
observation was further validated by counting the number of
viable trypan blue stained cells under the microscope as shown in
Figure 2.
Quantification of infected cells and intracellular viral RNA
load
Silenced and non-silenced monocytes were independently
infected with DENV-2 at a MOI of 2 in order to determine
whether silencing CD-14 associated molecule and/or clathrin
endocytosis pathway could inhibit DENV entry into monocytes
and, therefore, reduce its multiplication. We observed a marked
reduction in the percentage of infected cells, CD-14 associated
molecule, CLTC, and DNM2 silenced monocytes, by using flow
cytometry. The percentage of infected cells was reduced from
34.9%63.5 in non-transfected monocytes to 14.3%60.4 (59.0%),
12.7%60.3 (63.8%), and 18.5%63.6 (47.1%) in CD-14 associated
molecule, CLTC, and DNM2 silenced monocytes, respectively.
Interestingly, combined silencing (CD-14 associated molecule,
CLTC, and DNM2) of monocytes showed a higher inhibitory
effect on DENV entry and replication (5.1%60.6) which
represented 85.2% reduction in the percentage of infected cells
compared with non-silenced monocytes as shown in Figure 3
(One-way ANOVA with Dunnett’s post-test, P,0.0001). This
observation was further confirmed by RT-qPCR analysis. The
viral RNA load in silenced monocytes was compared to the non-
silenced monocytes and was normalized to the reference gene
(RPL22). Data is expressed as relative fold expression to non-
silenced monocytes, which was defined as 1.0 fold (viral RNA copy
number is 3.35610
3/ml). Results showed a significant reduction of
DENV RNA level in silenced monocytes: 0.57 fold60.10, 0.59
fold60.07, 0.39 fold60.18, and 0.73 fold60.05 in CD-14
associated molecule, CLTC, DNM2, and combined silenced
monocytes, respectively as shown in Figure 4 (One-way ANOVA
with Dunnett’s post-test, P,0.0001).
Quantification of culture supernatant viral RNA load
DENV excreted from the silenced monocytes into the culture
supernatant was titrated by RT-qPCR and compared to non-
silenced monocytes. Results showed a similar observation when
compared to the intracellular quantification results. Figure 5
Figure 1. Silencing efficiency of target genes. siRNA pools were proven to be specific and potent in silencing target genes. Each gene of the
target genes was targeted with a pool of siRNAs consisted of three different siRNAs. Results showed an efficient gene knockdown when compared
with non-transfected control and normalized to reference genes (One-way ANOVA with Dunnett’s post-test, P,0.0001, Error bars are 6 SD). The
effect of a combined transfection of the siRNA pools in monocytes is consistent, and there are no significant differences between separated
transfection, (82.4%61.9), (86.0%60.6), and (78.5%63.0), and combined transfection (82.7%62.4), (84.9%61.2), and (76.3%61.7), on expression of
CD-14 associated molecule, CLTC, and DNM2, respectively (Two-way ANOVA with Bonferroni post-test, P.0.05, Error bars are 6 SD). Scrambled siRNA
had no inhibitory effect on any gene expression and showed a similar expression to the non-transfected control.
doi:10.1371/journal.pntd.0001410.g001
siRNA Inhibition of Dengue Virus Entry
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silenced monocytes compared with non-silenced monocytes, which
is defined as 100% (viral RNA copy number is 1.06610
4/ml). The
reduction in viral RNA was 51.4%63.4, 63.7%62.9, 52.2%63.0,
and 63.0%65.5 for CD-14 associated molecule, CLTC, DNM2,
and combined silenced monocytes, respectively. This result is
statistically significant (One-way ANOVA with Dunnett’s post-
test, P,0.0001).
Discussion
We set off this study to determine the effect of RNAi in silencing
the monocytes attachment receptor, and clathrin-mediated
endocytosis to limit dengue infection. It was achieved through
monocytes isolation from peripheral blood and infection with
DENV-2 post siRNA transfection in vitro assay. Based on previous
observations, one of the main target cell type for in vivo DENV
infection is cells of the monocyte lineage [42]. It is responsible for
the dissemination of viruses and the production of more viruses
than other cells after its transmission via the mosquito vector
[8,9,43,44]. Macrophages are usually one of the first cell types to
pick up inoculated virus at the site of entry but, the stage of which
their differentiation is most susceptible to the virus entry is yet to
be deduced. A number of viruses can replicate in monocytes and
macrophages, and certain viruses replicate almost exclusively in
monocyte lineage. Virological studies have recognized that both
susceptibility to infection and viral gene expression increases
during monocytes maturation to macrophages and is closely
associated with persistence of latency of many viruses, such as
cytomegalovirus [45,46]. This shows that monocytes play an
important role during dengue infection, progression and severity of
the disease.
One of the biggest challenges of RNAi-based therapy is the
efficient delivery of siRNAs to the target cells. Effective delivery of
synthetic siRNAs requires elements that improve the pharmaco-
logical properties of the siRNA, and optimize all stages of the
delivery process once the initial injection through the sequence-
specific mRNA degradation in the cytoplasm of the target cells.
Successful applications of RNAi in functional genomics, proteo-
mics, and gene therapy depend on the efficiency of delivery of
siRNA into mammalian cells [47]. Delivery approaches using
cationic carriers, such as lipids, is the popular and practical
method for siRNA delivery in vitro. However, for application of
RNAi as a dengue therapeutic, an effective and cell-specific
delivery system, in vivo, is required. Recently, several studies have
described a success in siRNAs delivery, in vivo, by coupling to
antibodies or peptides that recognize cell surface receptors [48].
This can provide a further supporting and future potential for the
practical utility of this approach. Successful applications of RNAi
in functional genomics, proteomics, and gene therapy depend on
the efficiency of delivery of siRNA into mammalian cells [47]. The
aim of any therapeutic is to maximize the ratio of desired effects to
undesired effects. In some cases, such as chemotherapy, interferon
treatment and highly active antiretroviral treatment, the ratio is
not ideal and a significant degree of toxicity is associated with
treatment. Although RNAi has the capacity to provide better gene
targeting specificity, the exposure of cells to any exogenous
molecule (siRNA or transfecting reagent) has the potential to
disrupt normal cellular functions and needs to be carefully
controlled. In this study, we optimized the transfection experiment
that produced a maximum silencing effect at low-cell toxicity as
revealed by measurement of LDH released from cells with
compromised membrane and trypan blue dye in cell viability
assay. We also found that a low-siRNA concentration is optimal
and can achieve an efficient gene silencing. The approach of gene
silencing is a widely accepted technique and, recently, RNAi
technique had shown a potential to achieve the gene therapy goal
[49]. There are several advantages of RNAi therapeutics, which
include specific design targeted therapeutics for almost any gene
regardless of the function of the gene product. RNAi mediated
inhibition is more potent than that achieved with other antisense
oligonucleotides and the versatility and ease with which RNAi
mediated inhibition can induce multiple sequences within an
individual gene, or a group of genes, can be targeted simulta-
neously and more readily providing the benefit of combination
therapy [31]. Our results are in agreement with this point. We
Figure 2. Transfection cytotoxicity. Monocytes were exposed to siRNA at a concentration of 25, 50, and 50 nM for CD-14 associate molecule,
CLTC, and DNM2, respectively. Cytotoxicity was determined by measuring LDH level in the culture supernatant and by counting trypan blue stained
viable cells. Results showed siRNAs are not cytotoxic (.90% live cells) for all pools of siRNA. Combined transfection of different siRNAs also found not
cytotoxic to monocytes (90.5% live cells). No statistical significance was observed by One-way ANOVA analysis (P.0.05).
doi:10.1371/journal.pntd.0001410.g002
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targeting CD-14 associated molecule, CLTC and DNM2. Each
pool achieved its own silencing level and consistent efficient
knockdown of these genes in monocytes was achieved by co-
transfection of the three pools simultaneously. The desire to pool
three siRNAs was raised primarily from the finding that the
silencing efficiency of a single siRNAs lesser than combined pool of
triple siRNAs. This pools have shown a greater potency in the
reduction of the target gene expression and elimination off-targets
effect.
Focusing on the RNAi based therapeutic efficacy, one of the
potential weaknesses, is the problem of resistance and RNAi
escape mutations. This problem often results from using RNAi as
an antiviral agent, as it has been demonstrated that both RNA and
DNA viruses can quickly produce RNAi escape mutations [31].
This problem will probably necessitate the use of RNAi in
combination therapy approaches, including multiple RNAi target
sequences and/or other synergistic antiviral drugs. Another
possible alternative way to overcome viral resistance is to provide
a new therapeutic strategy by targeting the host factors known to
be involved in viral infection, such as entry receptor or binding
molecules on the susceptible cells. Thus, it is likely to suppress viral
infection by making the cellular receptors for viruses on human
cells less accessible. Dengue virus-host cell interaction is initiated
with the virus binding on attachment receptors on the cell surface,
followed by induction of signals that activate the endocytic
Figure 3. Quantification of infected cells by flow cytometry. At 72 h post-transfection, monocytes were infected by DENV-2 at MOI of 2.
Marked reduction in percentage of infected cells was observed. This figure shows the percentage of DENV infected cells at different conditions. (a)
Transfected non-infected monocytes (0.0%) represents the negative control. (b) Transfected mock-infected monocytes as a staining control (0.0%). (c)
Non-transfected infected monocytes (34.9%) as a positive control. (d) CD-14 associated molecule silenced infected monocytes (14.3%). (e) CLTC
silenced infected monocytes (11.1%). (f) DNM2 silenced infected monocytes (18.5%). (g) CD-14 associated molecule, CLTC, and DNM2 combined
silenced infected monocytes (5.1%). (h) Summarized the results of the flow cytometry experiments. Data is expressed as a percentage of infected cells
compared with non-transfected infected monocytes (NTI) which was defined as 100%. The percentages of the infected cells are 41.0%, 36.2%, 52.9%
and 14.8% for CD-14 associated molecule, CLTC, DNM2, and combined silenced monocytes, respectively (One-way ANOVA with Dunnett’s post-test,
P,0.0001, Error bars are 6 SD).
doi:10.1371/journal.pntd.0001410.g003
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entry into the cell and initiation of infection. This study was
designed to target the susceptible receptor (CD-14 associated
molecule), that assumed is responsible for attachment of DENV to
monocytes [8,16,22] and clathrin-mediated endocytosis that
known as the main pathway of viruses’ internalization [22].
Recent studies showed that design and synthesis of agents that
prevent DENV binding and entry to the cellular receptor sites
could prove to be novel antiviral agents of preventing the disease.
RNAi pathway shows a role in modulating DENV replication in
different cells. It was observed that down regulation of Hsp60 in
human monocytic myeloma cell line (U937) resulted in the
decrease of percentage of infected cells [50]. Silencing the cellular
genes involved in processes of endocytosis, cytoskeletal dynamics
and endosome trafficking in Huh7 cells showed a potential
inhibition of DENV [51], although these host targets weren’t
mentioned in the whole genome RNAi screens that have been
published recently for West Nile and DENV [52]. Moreover,
targeting the highly conserved sequence in the DENV envelope
gene by siRNA effectively suppressed DENV replication in
dendritic cells, macrophages [48] and C6/36 cells [53]. Significant
inhibition of dengue infection is achieved by silencing the CD-14
Figure 4. Intracellular dengue virus RNA load. Viral RNA levels were quantified by RT-QPCR and normalized to reference gene (RPL22). Data is
expressed as relative fold expression to non-transfected infected monocytes control, which defined as 1.0 fold. Results show (0.57 fold60.10), (0.59
fold60.07), (0.39 fold60.18), and (0.73 fold60.05) reduction in viral RNA load in CD-14 associated molecule, CLTC, DNM2, and combined silenced
monocytes, respectively (One-way ANOVA with Dunnett’s post-test, P,0.0001, Error bars are 6 SD). (TNI, Transfected Non-Infected; NTI, Non-
Transfected Infected; NTNI, Non-Transfected Non-Infected).
doi:10.1371/journal.pntd.0001410.g004
Figure 5. Extracellular dengue virus RNA load. DENV RNA in the culture supernatant of transfected and non-transfected monocytes was
quantified by RT-qPCR. Result shows marked reduction in viral RNA (51.4%, 63.7%, 52.2%, and 63.0%) for CD-14 associated molecule, CLTC, DNM2,
and combined silenced monocytes, respectively, when compared with non-transfected monocytes, which defined as 100% (viral RNA copy number is
1.06610
4/ml). This result is statistically significant (One-way ANOVA with Dunnett’s post-test, P,0.0001, Error bars are 6 SD). (TNI, Transfected Non-
Infected; NTI, Non-Transfected Infected; NTNI, Non-Transfected Non-Infected).
doi:10.1371/journal.pntd.0001410.g005
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endocytosis (up to 63.8%). Furthermore, more potent inhibition
is reached (up to 85.2%) by combined silencing (CD-14 associated
molecule, and clathrin-mediated endocytosis) simultaneously. This
reduction in viral yield was not due to cell death as could be
identified by cytotoxicity and viability tests (.90% live cells) in
both transfected and non-transfected monocytes. Failure to
achieve complete viral entry inhibition may be attributed to
different reasons such as the use of alternative secondary receptors
(such as Fc receptors and Hsp) or endocytosis pathways (such as
phagocytosis and caveolae-mediated endocytosis) to establish the
infection or incomplete inhibition by the RNAi machinery. For
RNAi based therapeutics designing, it is necessary to consider that
this technology knockdown gene expression, but in general does
not eliminate it. Therefore, for some conditions, incomplete down
regulation of a pathogenic gene seems to be adequate to produce
clinically appropriate improvement [31]. The incidence of fatal
DHF cases has been increased sharply especially in Asia over the
last two decades, making it a leading cause of morbidity by
inducing coagulopathy and vasculopathy [54]. One of the
principal virological characteristics of severe DHF patients is the
elevated viral load even during the defervescence stage [55]. This
study suggests that, targeting the entry of DENV using RNAi is an
attractive strategy for therapeutic intervention since it has a limit
cell toxicity and attack the virus at the first step of the replication
cycle. Moreover, another beneficial effect that could be expected is
the avoidance of damages that could occur to the cells later during
viral replication. Inevitably, reducing the entry of DENV into
monocytes could be helpful in reducing the severity and incidence
of the DHF by reducing the viremia during the infection course.
Furthermore, this study confirms the previous findings of the role
of CD-14 associated molecules and clathrin mediated endocytosis
in DENV entry in the host cells and establishing the infection.
Conclusions
We successfully inhibit the DENV entry and subsequent virus
multiplication in monocytes by silencing the surface receptor and
clathrin mediated endocytosis using RNA interference. This tool
might serve as a novel promising therapeutic agent for the
attenuation of dengue infection, which could subsequently leads to
the reduction of disease transmission as well as progression to
severe form of the disease DHF.
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